跳至主要内容
临床试验/NCT01449539
NCT01449539终止不适用

Pilot Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization

University of Arkansas2 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2012年2月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
终止
入组人数
8
试验地点
2
主要终点
Number of Stem Cells Collected

研究概览

简要总结

The purpose of this study is to evaluate the safety and efficacy of hyperbaric oxygen therapy (HBOT) as a therapeutic option in mobilizing stem cells for autologous stem cell transplant.

详细描述

Subjects will receive HBOT daily for 10 days in conjunction with standard growth factor treatment regimens for stem cell mobilization. The role of HBOT in stem cell mobilization as well as its role on oxidative stress will be evaluated.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who are being considered for autologous stem cell transplant as part of their routine care who have failed at least one prior attempt at stem cell mobilization with any of currently available standard regimens using growth factors.
  • Patients in who the use of Mozobil® is medically justified but is not possible because of insurance or financial reasons
  • Patients scheduled to begin standard growth factor treatment with Neupogen® as part of routine care.
  • Patients who have had a bone marrow evaluation performed within one month prior to enrollment as part of routine clinical care or under IRB#
  • Patients who have had a chest x-ray or CT Chest within 60 days prior to enrollment.
  • ECOG performance status ≤ 3 performed within 60 days prior to enrollment which will be determined by history.
  • Patients who are at least 18 years of age at the time of registration.
  • Patient must have signed an IRB-approved informed consent and understand the investigational nature of the study.

排除标准

  • Clinically significant hepatic dysfunction as noted by direct bilirubin or AST >3 times the upper normal limit or clinically significant concurrent hepatitis within 60 days prior to enrollment.
  • History of New York Heart Association (NYHA) Class III or Class IV heart failure
  • Recent (< 6 months) myocardial infarction, unstable angina, difficult to control congestive heart failure, uncontrolled hypertension, or difficult to control cardiac arrhythmias from medical history.
  • Untreated pneumothorax from medical history.
  • Uncontrolled seizure disorder from medical history
  • Uncontrolled insulin dependent diabetes (verified by routine labs in medical record)
  • History of severe claustrophobia
  • Severe COPD (FEV1 < 50% of predicted on pulmonary function test) performed within 60 days prior to enrollment
  • Untreated ear barotraumas from medical history
  • Pregnancy or currently breastfeeding (females of childbearing potential must agree to use adequate contraception during the study). A urine pregnancy test will be performed prior to initiating HBOT.
  • Patients currently receiving Bleomycin, Cisplatin, Disulfiram, Doxorubicin, and Sulfamylon.
  • Any other condition that the PI determines may jeopardize the safety of the subject during the course of the study

结局指标

主要结局

Number of Stem Cells Collected

时间窗: one week post-treatment

Total stem cells collected from all participants at one week post-study treatment

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验